

1 Prognostic value of sTREM-1 in COVID-19 patients: a biomarker 2 for disease severity and mortality

3 Pedro V. da Silva Neto^{1,2*}, Jonatan C. S. de Carvalho^{1,3*}, Vinícius E. Pimentel^{1,4*},
4 Malena M. Pérez^{1*}, Ingrid Carmona-Garcia^{3,5*}, Nicola T. Neto^{5*}, Diana M.
5 Toro^{1,2*}, Camilla N. S. Oliveira^{1,4*}, Thais F. C. Fraga-Silva⁴, Cristiane M. Milanezi⁴,
6 Lilian C. Rodrigues¹, Cassia F. S. L. Dias¹, Ana C. Xavier⁵, Giovanna S. Porcel⁵,
7 Isabelle C. Guarneri⁵, Kamila Zapparoli⁵, Caroline T. Garbato⁵, Jamille G. M.
8 Argolo⁵, Ângelo A. F. Júnior⁵, Alessandro P. de Amorim¹⁰, Augusto M.
9 Degiovani¹⁰, Dayane P. da Silva¹⁰, Debora C. Nepomuceno¹⁰, Rafael C. da
10 Silva¹⁰, Leticia F. Constant¹⁰, Fátima M. Ostini¹⁰, Marley R. Feitosa⁶, Rogerio S.
11 Parra⁶, Fernando C. Vilar⁷, Gilberto G. Gaspar⁷, José J. R. da Rocha⁶, Omar
12 Feres⁶, Rita C. C. Barbieri¹¹, Fabiani G. Frantz¹, Sandra R. Maruyama⁸, Elisa M.
13 S. Russo¹, Angelina L. Viana⁵, Ana P. M. Fernandes⁵, Isabel K. F. M. Santos⁴,
14 Vânia L. D. Bonato⁴, Marcelo Dias-Baruffi¹, Adriana Malheiro², Ruxana T.
15 Sadikot⁹, Cristina R. B. Cardoso^{1#}, Lúcia H. Faccioli^{1#} and Carlos A. Sorgi^{2,3#}.

16 ¹Departamento de Análises Clínicas, Toxicológicas e Bromatológicas. Faculdade de Ciências
17 Farmacêuticas de Ribeirão Preto – FCFRP. Universidade de São Paulo – USP, Ribeirão Preto,
18 SP, Brazil.

19 ²Programa de Pós-Graduação em Imunologia Básica e Aplicada – PPGIBA. Instituto de Ciências
20 Biológicas, Universidade Federal do Amazonas - UFAM, Manaus, AM, Brazil.

21 ³Departamento de Química. Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto –
22 FFCLRP. Universidade de São Paulo - USP, Ribeirão Preto, SP, Brazil.

23 ⁴Departamento de Bioquímica e Imunologia. Faculdade de Medicina de Ribeirão Preto - FMRP.
24 Universidade de São Paulo – USP, Ribeirão Preto, SP, Brazil.

25 ⁵Escola de Enfermagem de Ribeirão Preto – EERP. Universidade de São Paulo – USP, Ribeirão
26 Preto, SP, Brazil.

27 ⁶Departamento de Cirurgia e Anatomia, Faculdade de Medicina de Ribeirão Preto - FMRP,
28 Universidade de São Paulo (USP), Ribeirão Preto, SP, Brazil.

29 ⁷Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto - FMRP,
30 Universidade de São Paulo (USP), Ribeirão Preto, SP, Brazil.

31 ⁸Departamento de Genética e Evolução, Centro de Ciências Biológicas e da Saúde Universidade
32 Federal de São Carlos - UFSCar, São Carlos, SP, Brazil.

33 ⁹Department of Veterans Affairs, Division of Pulmonary and Critical Care Medicine, Emory
34 University, Atlanta, USA.

35 ¹⁰Hospital Santa Casa de Misericórdia de Ribeirão Preto, Ribeirão Preto, SP, Brazil.

36 ¹¹Hospital São Paulo, Ribeirão Preto, SP, Brazil.

37

38 * These authors contributed equally to this work

39 # These authors contributed equally to this work

40 Corresponding:

41 Carlos Arterio Sorgi, Ph.D – Departamento de Química - FFCLRP – USP –
42 Av. Bandeirantes, n.3900 – Ribeirão Preto / SP – 14040-901 – Brazil – Phone:
43 (16) 3315 9176 - E-mail: carlos.sorgi@usp.br

44 **Abstract**

45 **Background:** The uncontrolled inflammatory response plays a critical role in the
46 novel coronavirus disease (COVID-19) and triggering receptor expressed on
47 myeloid cells-1 (TREM-1) is thought to be intricate to inflammatory signal
48 amplification. This study aims to investigate the association between soluble
49 TREM-1 (sTREM-1) and COVID-19 as a prognostic biomarker to predict the
50 disease severity, lethality and clinical management. **Methods:** We enrolled 91
51 patients with COVID-19 in domiciliary care (44 patients) or in hospital care (47
52 patients), who were classified after admission into mild, moderate, severe and
53 critical groups according to their clinical scores. As non-COVID-19 control, 30
54 healthy volunteers were included. Data on demographic, comorbidities and
55 baseline clinical characteristics were obtained from their medical and nurse
56 records. Peripheral blood samples were collected at admission and after
57 hospitalization outcome to assess cytokine profile and sTREM-1 level by specific
58 immunoassays. **Results:** Within COVID-19 patients, the highest severity was
59 associated with the most significant elevated plasma levels sTREM-1. Using
60 receiver operating curve analysis (ROC), sTREM-1 was found to be predictive of
61 disease severity (AUC= 0.988) and the best cut-off value for predicting in-hospital
62 severity was ≥ 116.5 pg/mL with the sensitivity for 93.3% and specificity for
63 95.8%. We also described the clinical characteristics of these patients and
64 explored the correlation with markers of the disease aggravation. The levels of
65 sTREM-1 were positively correlated with IL-6, IL-10, blood neutrophils counts,
66 and critical disease scoring ($r= 0.68$, $p<0.0001$). On the other hand, sTREM-1
67 level was significantly negative correlated with lymphocytes counting, and mild
68 disease ($r= -0.42$, $p<0.0001$). Higher levels of sTREM-1 were related to poor
69 outcome and death, patients who received dexamethasone tended to have lower
70 sTREM-1 levels. **Conclusion:** Our results indicated that sTREM-1 in COVID-19
71 is associated with severe disease development and a prognostic marker for
72 mortality. The use of severity biomarkers such as sTREM-1 together with patients
73 clinical scores could improve the early recognition and monitoring of COVID-19
74 cases with higher risk of disease worsening. **Key words:** COVID-19; sTREM-1;
75 Inflammation; Biomarker; Severity; Mortality.

76

77 Introduction

78 The new coronavirus disease (COVID-19), caused by severe acute
79 respiratory syndrome coronavirus 2 (SARS-CoV-2), it became a worldwide public
80 health problem due to high rates of morbidity and mortality. Approximately 80%
81 of patients infected with SARS-CoV-2 may have mild symptoms or are
82 asymptomatic. However, the virus is capable of causing serious clinical
83 manifestations, such as acute respiratory distress syndrome (ARDS),
84 cardiovascular and coagulopathy disorders and shock; resulting in multi-organ
85 system dysfunction in some patients (1–10). Patients with older ages, male
86 gender, obesity, and chronic comorbidities such as cardiovascular disease,
87 diabetes, chronic respiratory disease, and cancer were more likely to have worse
88 outcomes (11–13). Moreover, patients with COVID-19 present multiple
89 hematological abnormalities, of which lymphopenia and thrombocytopenia were
90 prominent (14).

91 Similar to SARS, inflammation plays a major role in the pathophysiology of
92 COVID-19 and patients exhibiting severe disease may have systemic high
93 concentrations of inflammatory makers in serum samples, such as IL-6, TNF- α ,
94 C-reactive protein (CRP) and D-dimer (10,15–21). Pathogen infections generate
95 an innate response that is initiated by the recognition of pathogen-associated
96 molecular patterns (PAMPs) by pattern recognition receptors (PRRs) followed an
97 antigen-specific adaptive immune response. Both innate and adaptive immune
98 responses induce the activation of cell receptors and soluble mediators that
99 trigger inflammation and its balance is critical for controlling tissue damage (22).
100 Significant evidence indicates that a dysregulated immune and inflammatory
101 response contributes to the clinical presentation of patients with severe COVID-
102 19 disease.

103 Triggering receptor expressed on myeloid cells 1 (TREM-1) is a member of
104 the immunoglobulin superfamily expressed in myeloid and epithelial cells. TREM-
105 1 activation induces secretion of TNF- α , IL-6, IL-1 β , IL-2, IL-12p40 by monocytes,
106 macrophages and dendritic cells, enhancing inflammation during infections by
107 different pathogens, namely Influenza A virus, Dengue virus, Hepatitis C virus,
108 *Plasmodium falciparum*, *Staphylococcus aureus* and *Pseudomonas aeruginosa*
109 (23–29). Immune responses against to virus and bacterial are modulated by

110 activation of TREM-1 in macrophages. TREM-1 KO mice are protected from
111 severe influenza although viral clearance is unaltered (30). Similarly, HIV
112 infection, or even exposure to the HIV proteins, Tat or gp120, in the absence of
113 infection (31) induce expression of TREM-1 suggesting that TREM-1 may have
114 a pathogenic role in viral infections and immune response.

115 Soluble form of the TREM-1 (sTREM-1) has been reported in plasma
116 samples during infection and inflammation (32–35). The sTREM-1 is a 27kDa
117 polypeptide in which the extracellular domain is released from the cell
118 surface by action of metalloproteinases (36). Interestingly, the serum sTREM-1
119 level measurements could be a valuable diagnostic biomarker and may be useful
120 in predicting severe prognosis in diseases related to inflammatory processes, as
121 seen in septic patients, Hepatitis B virus, Human Immunodeficiency virus (HIV),
122 Crimean Congo Hemorrhagic Fever and *Mycobacterium tuberculosis infections*
123 (27,33,37–39).

124 Given that SARS-CoV-2 infection induces a hyper-inflammatory response,
125 we hypothesized that TREM-1 activation in the COVID-19 illness triggers
126 upregulation and shedding into sTREM-1. Because, sTREM-1 has been
127 validated as prognostic markers in various inflammatory disorders, we performed
128 herein a prospective study to investigate the prognostic utility of sTREM-1 in
129 patients with COVID-19, as an important biomarker that can predict disease
130 severity and qualify effective interventions for managing patients that need
131 intensive supportive care upon hospitalization.

132 MATERIAL AND METHODS

133 Study Design and subjects

134 This prospective study was conducted at *Hospital Santa Casa de Misericórdia of*
135 *Ribeirão Preto* and *Hospital São Paulo of Ribeirão Preto - Brazil* from April to
136 August of 2020 and was conducted with strict and reasonable inclusion and
137 exclusion criteria. The patient inclusion criteria were adults (aged over 18 years),
138 positive for SARS-CoV-2 infection that understood and agreed to enroll in this
139 study. Controls (healthy adult volunteers) were tested negative for SARS-CoV-2.
140 The exclusion criteria were individuals younger than 18 years of age and

141 pregnant or lactating women. In total, 30 control subjects were enrolled at the
142 beginning of the COVID-19 pandemic with a negative test for SARS-CoV-2 and
143 91 patients with a positive test for SARS-CoV-2, using genomic RNA assay
144 performed in a nasopharyngeal/oropharyngeal swab RT-PCR (Kit Biomol
145 OneStep/COVID-19) or serology specific IgM and IgG antibodies (SARS-CoV-2
146 antibody test[®], Guangzhou Wondfo Biotech, China).

147 **Data collection**

148 Members of our team carefully collected and reviewed the medical records of
149 each patient. The data were searched and compiled from the electronic medical
150 and nursing record systems. We included sociodemographic information,
151 comorbidities, medical history, clinical symptoms, routine laboratory tests,
152 immunological tests, chest computed tomography (CT) scans results, clinical
153 interventions, and outcomes. These informations were documented on a
154 standardized record form. Data collection of laboratory results was defined using
155 the first-time examination at admission (within 24 h after admission), defined as
156 primary endpoint, and the secondary endpoint was clinical outcome (death or
157 recovery).

158 **Severity assessment**

159 Clinically, severity of the COVID-19 patients was classified into mild, moderate,
160 severe, and critical ill according to the statement in the Novel Coronavirus
161 Pneumonia Diagnosis and Treatment Guideline (7th ed.), with modifications (40).
162 The clinical manifestations were categorized as: i) mild group - positive for SARS-
163 CoV-2 infection, with or without the following symptoms: diarrhea, cough, fever,
164 headache, loss of taste (ageusia)/ smell (anosmia), myalgia, nausea, and
165 vomiting, oxygen saturation between 94-99 % on room air; ii) moderate group -
166 patients having manifestation of mild disease, with symptoms including dyspnea,
167 oxygen saturation $\geq 93\%$ on room air and arterial partial pressure of oxygen
168 (PaO_2)/ oxygen concentration (FiO_2) between 250-300 mmHg, do not need
169 invasive ventilation, allegedly using nasal-cannula oxygen (2-4 L/min) or oxygen
170 masks ventilation (4-12 L/min); iii) severe group - possible admission to intensive-

171 care units, severe respiratory distress, oxygen saturation < 93% on room air and
172 PaO₂/ FiO₂ < 250mmHg, need non-invasive ventilation, such as oxygen masks
173 ventilation (10-15 L/min); and iv) critical group - admission to intensive-care units,
174 acute respiratory distress syndrome, need invasive ventilation, PaO₂/ FiO₂
175 <200mmHg, with or without one or more additional parameters: need
176 hemodialysis, sepsis, septic shock, and multiorgan dysfunction (41).

177 **Laboratory Methods**

178 Blood samples were collected by venipuncture in tubes with vacuum collection
179 system. Two tubes (5mL capacity) were collected from each patient: one tube
180 containing EDTA anticoagulant (BD Vacutainer® EDTA K2 Franklin Lakes, New
181 Jersey, USA) to perform hematological tests, and a tube containing heparin
182 anticoagulant (BD SST® Gel Advance® Franklin Lakes, New Jersey, USA) to
183 obtain plasma used to quantify levels of circulating protein mediators by flow
184 cytometry or ELISA assay. Plasma was separated from whole blood samples and
185 stored in a -80°C freezer. The clinical laboratory investigation included a complete
186 blood count and biochemical serum tests (including liver and kidney function), as
187 well as the determination of the coagulation factors and myocardial enzyme
188 spectrum.

189 **Cytokines measurement**

190 The cytokines IL-6 and IL-10 were quantified by the Cytometric Bead Array
191 technique, according to the manufacturer's specifications (BD™ Human
192 Inflammatory Cytokine CBA Kit, Catalog No. 551811, Lot: 9341655). Briefly, 50µl
193 of plasma samples were mixed with capture antibody-coupled beads, and then
194 50µl fluorescent labeled (PE) detection antibodies. The samples were mixed and
195 incubated at room temperature in the dark. After 3 h incubation, the beads were
196 washed and resuspended with PBS 1% paraformaldehyde (*v/m* – Sigma
197 Chemical Co. St. Louis, MO – USA). A recombinant protein standard for each
198 cytokine that provides an internal control was included. The detection range of
199 each cytokine was 2.5 pg/ml to 5000 pg/ml. Data acquisition was performed using
200 a FACSCanto II flow cytometer (FACS Canto™II – BD Biosciences, San Diego,

201 CA, USA). Data was analyzed using FCAP Array 3.0 software and expressed as
202 mean fluorescence intensity (MIF) for each serum cytokine (BD Biosciences, San
203 Diego, CA, USA).

204 **Serum sTREM-1 assay**

205 Circulating level of sTREM-1 were measured in plasma by an established
206 available enzyme linked immunosorbent assay kit (DuoSet- Human TREM-1,
207 R&D System, Minneapolis, USA), with a detection range of 93.8 – 6,000 pg/mL.
208 The methodology was in according to the protocol described by the manufacturer
209 (R&D Systems, Minneapolis, MN).

210 **Computation of Correlation Matrix**

211 The dependence of multiple variables: sTREM-1 release (pg/mL); oxygen
212 saturation (sO₂ %); age (years); neutrophil count (x 10⁹ cells/L); lymphocytes
213 count (x 10⁹ cells/L); hypertension (systole); glycemia (mg/dL); male gender;
214 clinical scores (mild, moderate, severe and critical); IL-6 (pg/mL) and IL-10
215 amount (pg/mL); was calculated using Pearson correlation with cor() function in
216 R (version 4.0.2) through RStudio (version 1.1.463). The computed correlation
217 matrix was graphically displayed using corrplot function from R package “corrplot”
218 (Version 0.84) (42). Correlation coefficients (r) and *p*-values of the correlation
219 matrix were formatted and tabulated using Hmisc R package (43) and the values
220 available at Supplemental Table S2.

221 **Statistical analysis**

222 Data is presented as either counts or percentages (%) (for categorical) or median
223 (IQR) and standard deviations (SD) for continuous data. Intergroup comparisons
224 were made by the Mann-Whitney *U* test (non-normally distributed continuous
225 variables) and chi-square test or Fischer’s exact test for categorical variables.
226 One-way analysis of variance nonparametric test (Kruskal–Wallis test) was used
227 for multiple comparisons. The accuracy of predictor was determined by area
228 under the receiver operating characteristic (ROC) curve (AUC). The AUCs, with
229 95% confidence intervals, were computed to assess the diagnostic values of

230 sTREM-1; AUCs > 0.70 were considered clinically relevant. Comparative analysis
231 between groups was performed using GraphPad Prism™ software (version 8.4.2)
232 (San Diego, CA, USA). Statistical test differences were considered significant if
233 the *p* values were < 0.05.

234 **Ethical approval**

235 The procedures followed in this study were approved by the institutional ethics
236 board of *Faculdade de Ciências Farmacêuticas de Ribeirão Preto – Universidade*
237 *de São Paulo* and Brazil National Ethics Committee (CONEP, CAAE:
238 30525920.7.000.5403). Written informed consent was obtained from recruited
239 participants of the study.

240 **RESULTS**

241 *Demographic data, initial clinical signs and laboratory characteristics of study* 242 *subjects*

243 In total, 91 patients with laboratory-confirmed COVID-19 and 30 healthy
244 volunteers were recruited to the study (Table 1). In this study population, 44
245 patients were diagnosed with mild disease with residential care and 47 patients
246 with severe disease with hospital care on admission. The median age was 32.0
247 years (range, 23–80) for healthy volunteers and 49.0 years (range, 18–94) for all
248 patients infected with SARS-CoV-2. The average age was significantly higher in
249 the hospitalized patients than in residential care patients (Table 1). There was
250 significant difference in the female ratio between the healthy control group and
251 hospitalized COVID-19 patients (Table 1). Most patients had comorbidities or
252 coexisting disorders, including hypertension (29.6%), heart disease (10.9%),
253 diabetes (18.6%), neurological disorders (6.5%), cancer (5.4%), history of
254 smoking (19.7%), and history of stroke (3.2%). The number of comorbidities was
255 significantly higher in COVID-19 patients than in control group or in hospitalized
256 patients compared to residential care subjects (Table 1).

257 Generally, the most common initial symptoms in COVID-19 patients were
258 cough (62.6%), dyspnea (47.2%) and dysgeusia (35.1%), followed by diarrhea,
259 fever, muscle soreness, and hyperactive delirium (Table 1). In addition, the
260 absolute number of erythrocytes, hemoglobin, neutrophils, lymphocytes and

261 monocytes in the COVID-19 patients group were significant different than that in
 262 the control group, while the glycemic level was significant difference between the
 263 residential care and hospital care groups (Figure 1). The median time of
 264 hospitalization for COVID-19 patients was 10 days and some patients needed
 265 intensive care (42.5%). Also, those hospitalized patients received respiratory
 266 support: nasal-cannula oxygen (48.9%), oxygen masks ventilation (27,6%) and
 267 invasive mechanical ventilation (23.4%). The oxygen saturation was significantly
 268 lower in the hospitalized patients than in residential care patients (Table 1). The
 269 most common pharmacological treatments for COVID-19 patients were
 270 azithromycin (56.0%), dexamethasone (45.0%), ceftriaxone (41.7%), oseltamivir
 271 (37.3%), followed by cloroquine/hydroxychloroquine, ivermectin and
 272 anticoagulant.

273 **Table 1. Demographics and clinical characteristics of patients infected with**
 274 **SARS-CoV-2.**

Baseline Variable	Healthy Controls N= 30	All patients N= 91	COVID-19 care		P Value
			Residential N=44	Hospital N=47	
Demographic characteristics					
Age median \pm SD, (IQR)	32.0 \pm 14.1 (23-80)	49.0 \pm 19.7 (18-94)	37.0 \pm 10.7 (18-59)	66.0 \pm 16.0 (30-94)	^a 0.0002 ^{b,c} < 0.0001
Gender, No. (%)					
Male	17 (56.6)	46 (50.2)	15 (34.0)	31 (65.9)	^a 0.6744
Female	13 (43.3)	45 (49.4)	29 (65.9)	16 (34.0)	^c 0.0033
Comorbidities or coexisting disorders, No. (%)					
Hypertension	4 (13.3)	27 (29.6)	2 (4.5)	25 (53.1)	^a 0.0934 ^c < 0.0001
Cardiovascular disease	3 (10.0)	10 (10.9)	5 (11.3)	5 (10.6)	^a 1.0000 ^c 1.0000
Diabetes mellitus	1 (3.3)	17 (18.6)	4 (9.0)	13 (27.6)	^a 0.0419 ^c 0.0311
History of smoking	7 (23.3)	18 (19.7)	4 (9.0)	14 (29.7)	^a 0.7952 ^c 0.0175
History of stroke	-	3 (3.2)	-	3 (6.3)	-
Neurological	-	6 (6.5)	2 (4.5)	4 (4.8)	^c 0.6778
Cancer	-	5 (5.4)	-	5 (10.6)	-
Presenting symptoms, No. (%)					
Dyspnea	-	43 (47.2)	16 (36.3)	27 (57.4)	^c 0.1983
Fever	-	18 (19.7)	1 (2.2)	17 (36.1)	^c < 0.0001
Myalgia	-	11 (12.0)	-	11 (23.4)	-
Diarrehea	-	28 (30.7)	18 (40.9)	10 (21.2)	^c 0.0681
Cough	-	57 (62.6)	32 (72.7)	25 (53.1)	^c 0.0822
Hyperactive Delirium	-	3 (3.2)	-	3 (6.3)	-
Dysgeusia	-	32 (35.1)	28 (63.6)	4 (8.5)	^c < 0.0001
Laboratory findings, median \pm SD, (IQR)					
Erythrocytes x 10 ¹² /L	5.0 \pm 0.5 (4.00-5.90)	4.5 \pm 0.8 (2.23-5.89)	4.8 \pm 0.4 (3.77-5.89)	3.9 \pm 0.8 (2.23-5.67)	^a 0.0011 ^b < 0.0001


Hemoglobin (g/dL)	15.1 ± 1.5 (11.30-17.50)	13.7 ± 2.6 (6.60-18.20)	14.6 ± 1.2 (12.70-18.20)	11.8 ± 2.6 (6.60-16.20)	^a 0.0006 ^b < 0.0001
Leukocytes x 10 ⁹ /L	7.6 ± 2.1 (4.10-13.44)	8.1 ± 4.5 (1.60-26.10)	7.7 ± 2.4 (3.24-13.58)	9.0 ± 5.6 (1.60-26.10)	^a 0.5548 ^b 0.1342
Neutrophils x 10 ⁹ /L	57.4 ± 8.3 (36.00-74.60)	68.1 ± 16.0 (32.30-93.00)	57.2 ± 10.3 (32.30-77.80)	82.0 ± 8.2 (56.10-93.00)	^a 0.0001 ^b < 0.0001
Lymphocytes x 10 ⁹ /L	32.1 ± 8.3 (11.80-48.40)	20.5 ± 14.2 (1.00-58.00)	33.1 ± 9.3 (18.10-58.00)	9.7 ± 6.2 (1.00-31.80)	^a 0.0004 ^b < 0.0001
Monocytes x 10 ⁹ /L	7.2 ± 2.0 (3.80-13.00)	6.1 ± 2.9 (0.0-12.90)	7.0 ± 1.9 (3.20-11.20)	5.0 ± 3.3 (0.0-12.90)	^a 0.0054 ^b 0.0001
Platelets x 10 ⁹ /L	219.5 ± 39.67 (129.0-297.0)	222.0 ± 96.2 (9.10-620.0)	231.9 ± 61.0 (119.0-365.0)	242.6 ± 121.7 (9.10-620.0)	^a 0.6639 ^b 0.8674
Glycemia (mg/dL)	94.5 ± 43.74 (76.00-244.0)	99.0 ± 80.8 (9.0-479.0)	89.0 ± 69.1 (65.00-479.0)	115.5 ± 89.0 (9.0-467.0)	^a 0.9968 ^c 0.0035
Hospital support, No. (%)					
Infirmary	-	27 (29.6)	-	27 (57.4)	-
Intensive care unit (ICU)	-	20 (21.9)	-	20 (42.5)	-
Hospitalization data, No.					
Hospitalization days, median(IQR)	-	10 (1-34)	-	10 (1-34)	-
Respiratory support received (%)					
Nasal-cannula oxygen	-	23 (25.2)	-	23 (48.9)	-
Oxygen masks/ Noninvasive	-	13 (14.2)	-	13 (27.6)	-
Invasive mechanical ventilation	-	11 (12.0)	-	11 (23.4)	-
Oxygen Saturation median ± SD (IQR)	97 ± 1.7 (92-99)	92 ± 9.2 (54-99)	97 ± 2.3 (90-99)	86 ± 11.0 (54-99)	^a 0.0015 ^{b,c} < 0.0001
Medications No. (%)					
Dexamethasone	-	41 (45.0)	5 (11.3)	36 (76.5)	^c < 0.0001
Azithromycin	-	51 (56.0)	13 (29.5)	38 (80.8)	^c < 0.0001
Ceftriaxone	-	38 (41.7)	-	38 (80.8)	-
Oseltamivir	-	34 (37.3)	5 (11.3)	29 (61.7)	^c < 0.0001
Cloroquine/Hydroxychloroquine	-	12 (13.1)	-	12 (25.5)	-
Anticoagulant	-	3 (3.2)	-	3 (6.3)	-
Ivermectin	-	7 (7.6)	7 (15.9)	-	-

275 Abbreviation: SD: Standard deviation; Data are median (IQR), n (%), or n/N. ^aComparing the healthy
 276 controls group with all patients; ^bComparing the healthy controls group with residential and hospital
 277 COVID-19 patients, ^cComparing the residential group with hospitalized subjects. Patients' data were
 278 compared using χ^2 test, or Fisher's exact test for categorical variables and one-way analysis of
 279 variance (ANOVA) Mann-Whitney, nonparametric *t*-test application was used for continuous variables.
 280 $p < 0.05$ was considered statistically significant.

281 *sTREM-1 release is significantly associated with disease severity*

282 The potential role of sTREM-1 in regulating infectious diseases has been
 283 extensively investigated elsewhere. Here, we compared the levels of sTREM-1
 284 in plasma samples from control group and COVID-19 patients, and also,
 285 assessed the correlation with severity illness. As shown in Figure 1A, sTREM-1
 286 values were higher in patients with COVID-19 and significantly different in
 287 hospitalized group when compared with healthy volunteer controls, indicating an
 288 activation of immune response against SARS-CoV-2 infection. To evaluate the
 289 prognostic value of sTREM-1 in patients with COVID-19, ROC curves were drawn
 290 for patients with COVID-19 in residential and hospital care versus healthy
 291 controls.

292 The area under ROC curve of sTREM-1 for residential care patients, which
293 represent mostly the mild disease, was proximal to the considered value for
294 clinical relevance (AUC= 0.691); the preoperative concentration of ≥ 69.5 pg/mL
295 was the optimal cutoff value for predicting COVID-19 (sensitivity = 71.43 (54.9–
296 83.6)%, specificity = 54.1%); the positive predictive values (PPV) of 91.6 (60.2–
297 98.7)% and the negative predictive values (NPV) of 48.9 (43.0–54.9)% were
298 described (Figure 1B). However, the area under ROC curve of sTREM-1 for
299 hospital care patients, which denote the severe disease, was higher for clinical
300 relevance (AUC= 0.988); the sTREM-1 cut-off value of ≥ 116.5 pg/mL yielded
301 sensitivity of 93.3 (82.1–97.7)%, specificity of 95.83%, the PPV of 97.5 (85.4–
302 99.6)%, and the NPV of 82.1 (66.7–91.4)% for differentiating patients with
303 COVID-19 from those healthy subjects (Figure 1B). The plotted relative frequency
304 of patients to sTREM-1 production, showed a high number of events for low level
305 of sTREM-1 in residential care patients (mean = 113.68 pg/mL), and a spreader
306 number of events for high levels of sTREM-1 in hospital care patients (mean =
307 325.18 pg/mL), considering a intersection phase between residential and
308 hospitalized patients with COVID-19 (Figure 1C). Those results indicated the
309 sTREM-1 as a potential marker predictive of COVID-19 severity illness.



310


311 **Figure 1. The values of sTREM-1 in COVID-19 patients are elevated.** (A) The plasma
 312 concentration of sTREM-1 from COVID-19 patients with residential (n=44); or hospital
 313 care (n=47); and healthy controls (n=30) were analyzed and compared with each other. Median with
 314 range was presented. One-way analysis of variance nonparametric test (Kruskal–Wallis test) was
 315 used for multiple comparisons when data were not normally distributed. The differences between
 316 each group were presented with a p value in the graphic above the diagram. (B) ROC curves
 317 sTREM-1 for predicting disease on residential care (blue) and hospital care (red) patients with
 318 COVID-19. The area under the curve (AUC) and the comparative p value between COVID-19
 319 patients and control group was designated in the graphic. (C) Relative frequency of residential
 320 care (blue) and hospital care (red) on sTREM-1 release in COVID-19 patients. The mean,
 321 standard deviation, CL lower 95% and CL upper 95% data of each group were presented in the
 322 table under the diagram.

323 *Correlation of sTREM-1 with disease severity, comorbidities and inflammatory*
 324 *mediators in COVID-19 patients*

325 Subgroup analysis correlation of sTREM-1 in adverse outcome prediction
 326 was performed for patients according to different disease severity on admission.
 327 In this case, oxygen saturation (sO₂), age, neutrophil count, lymphocytes count,
 328 hypertension, glycemia, male gender, clinical scores, IL-6 and IL-10 were
 329 identified as independent risk factors of adverse outcome in patients with COVID-
 330 19. For this, we performed analyses using the level of sTREM-1 in 91 patients'

331 plasma obtained during the period of SARS-CoV-2 infection diagnostic
332 confirmation. In figure 2A, a correlation plot using correlation matrix (r values)
333 showed statistically positively association of sTREM-1 level with critical disease,
334 neutrophils count, age, and IL-10, IL-6 production. Conversely, we also observed
335 a statistically negative association of sTREM-1 with mild disease and
336 lymphocytes count. Full r and p -values of the correlation matrix are available in
337 Supplemental Table S2. To further examine if higher sTREM-1 contributes to
338 disease severity, we next analyzed sTREM-1 level in COVID-19 patients
339 subgroups based on disease severity (Figure 2B). Despite significant differences
340 between critical and severe or moderate and to mild groups, such significance
341 was not seen for comparison between moderate and mild patients.

342 As expected, in figure 2C we demonstrated a positive correlation between
343 sTREM-1 and neutrophils count, IL-10 and IL-6 levels. However, when comparing
344 these independent risk factors with the adverse outcome in patients with COVID-
345 19, we observed a homogeneity values for mild and moderate disease (Gate 1),
346 and variable increased levels for severe (Gate 2) and critical disease (Gate 3).
347 On this way, we suggested that sTREM-1 value is a better predictor of clinical
348 outcome of the disease than other risk factors or inflammatory mediators. In
349 addition, sTREM-1 negatively correlated with lymphocyte count; and as
350 assumed, sTREM-1 levels improved the discrimination between the
351 mild/moderate to severe and critical group when compared to total lymphocytes
352 number. Interesting, we observed that the glycemia index was higher in severe
353 group than in mild/moderate and critical group, indicating that a single analysis of
354 glycemia cannot be used to classify adequately all the COVID-19 severity
355 ranges.



356

357 **Figure 2. Clinical and immunological parameters strictly correlated with sTREM-1 levels in**
 358 **COVID-19 patients. (A)** Correllogram of sTREM-1 and cytokine levels in the plasma of COVID-
 359 19 patients with comorbidities and clinical characteristics. Color scale sidebar indicates the
 360 correlation coefficients (r), where blue means positive correlation and red means negative
 361 correlation. Square size and color intensity are proportional to the correlation coefficients.
 362 Statistically significant correlations of pairwise variable comparisons are indicated by *p < 0.05,
 363 **p < 0.01 and ***p < 0.001. **(B)** The level of sTREM-1 in COVID-19 patients with different severity:
 364 mild (n = 23), moderate (n = 21), severe (n = 28) and critical (n = 19) group. Median with ranges


365 was presented. One-way analysis of variance nonparametric test (Kruskal–Wallis test) was used
366 for multiple comparisons when data were not normally distributed. The differences between each
367 group were presented with a p value in the graphic above the diagram. (C) The correlation of
368 plasma sTREM-1 and lymphocytes count, glycemia, neutrophils count, IL-10 and IL-6 amount in
369 patients with COVID-19 was represented by a dot-plot graphic. The lines indicated the median
370 value of different variables of all patients. Gates are placed around populations with common
371 characteristics of patients with COVID-19.

372 *Added Prognostic Value of sTREM-1 to predict mortality risk in COVID-19*

373 To perform longitudinal analysis, sTREM-1 in patients with COVID-19 was
374 further monitored during hospitalization. To better view the overall changes of
375 sTREM-1 level, the plasma concentrations in the admission (baseline level) and
376 after in the outcome treatment (death or recovery) were compared (Figure 3A).
377 Of note, mostly patients treated with dexamethasone showed a reduced or
378 stabilized sTREM-1 release after treatment, with only two-outcome recovery
379 patient. In contrast, plasma sTREM-1 was significantly elevated in patients with
380 COVID-19 who were not treated with dexamethasone. Notably, no recovery
381 outcome was observed in these subjects and thus this analysis showed that
382 sTREM-1 was a significant predictor of mortality.

383 In figure 3B, we showed our cohort of COVID-19 hospital pharmacological
384 therapies. Although there are no approved treatments for COVID-19, the hospital
385 protocols issued for antibiotics, antivirals and anti-inflammatory drugs. While
386 treatment in this study was not stratified by severity of disease, 14 hospitalized
387 patients in this cohort longitudinal analysis have been treated with
388 dexamethasone (73.68%); 14 patients with antibiotics (azithromycin/ceftriaxone
389 73.68%), 12 patients with oseltamivir (63.15%), 5 patients with
390 hydroxycloquine/cloroquine (26.3%) and 1 patient treated with anticoagulant
391 (5.2%). The combined pharmacology approach for these patients with COVID-19
392 was represented by a Venn diagram (Figure 3B). Changes in oxygen support
393 level from hospital admission to recovery or death were showed in Figure 3C. In
394 our cohort, 9 patients were in hospital infirmary care (47.3%) and 10 patients
395 were in intensive care unit (52.63%). Among those patients, 6 were on invasive
396 mechanical ventilation (31.5%), 8 on oxygen masks non-invasive ventilation
397 (42.1%) and 5 on oxygen nasal-cannula (26.3%) during hospitalization. The

398 details of hospital support and supportive therapies for patients with COVID-19
 399 were demonstrated in Supplemental Table 1.



400
 401 **Figure 3. The kinetics of sTREM-1 in COVID-19 patients during hospitalization.** (A) The plasma
 402 sTREM-1 level of critical patients during hospitalization was presented. The graphics indicated the
 403 individually value of sTREM-1 in the day of hospital-admission and after in the disease outcome, that can
 404 be death (+) or recovery (-). The individuals were segmented according with pharmacology treatment in
 405 dexamethasone-treatment and non-treatment with dexamethasone. Each circle indicates an individual
 406 patient. Nonparametric *t* test (Mann-Whitney U test) was used to data not normally distributed. The
 407 differences between the groups were presented with a *p* value in the graphics. (B) Venn diagram showed
 408 all pharmacological treatment relations between dexamethasone, Oseltamivir, Piperacillin+Tazobactam,
 409 Hydroxycloquine/cloroquine, Azitromycin/Ceftriaxone of different sets patients with COVID-19 in hospital
 410 care. (C) Demonstrative percentages of patients in distinctive hospital and respiratory support during
 411 hospitalization.

412 **DISCUSSION**

413 To date, the most significant predictors of COVID-19 disease severity are
414 relate to either activation or suppression of the host immune response (44,45). In
415 the present study, we show for the first time in a population of patients in the city
416 of Ribeirão Preto - Brazil with COVID-19 that plasma sTREM-1 concentrations
417 might be a predictive factor and a biomarker for disease severity. Plasma sTREM-
418 1 concentrations were gradually increased from mild to moderate, severe and
419 critical forms of COVID-19. Indeed, ROC analysis confirms that sTREM-1 was an
420 important predictor of disease progression in COVID-19 patients.

421 TREM-1 exhibit the ability to amplify proinflammatory innate immune
422 response, such as by the Toll like receptors (TLR), which recognize a wide range
423 of bacterial, fungal and viral components (46). In addition to neutrophils,
424 monocytes and macrophages, TREM-1 is also expressed in epithelial and
425 endothelial cells (25). Elevated sTREM-1 level are indicative of acute and chronic
426 conditions including sepsis and pneumonia (47,48). Enhanced inflammatory
427 response in macrophages was indicated as a mechanism by which TREM-1
428 signaling contributes to lung injury, suggesting that TREM-1 inhibition was a
429 potential therapeutic target for neutrophilic lung inflammation and acute
430 respiratory distress syndrome (ARDS) (49). Moreover, sTREM-1 level in sepsis
431 could reflect an essential immune dysfunction, where excessive cleavage of
432 TREM-1 could contribute to immunosuppression and death during a severe
433 infection (50). Since severe infections can occur by multiple microorganism the
434 broad prognostic of sTREM-1 implied its potential as a severity marker for all-
435 cause febrile illness (51). However, fever was not the mostly common signs in
436 admission patient with COVID-19 in our cohort, especially in mild and moderate
437 disease. Thus, sTREM-1 has been recognized to be a valuable diagnostic and
438 prognostic marker since it is easily detected using immunochemical assays.
439 Nevertheless, the role of sTREM-1 in patients with COVID-19 remains unclear.

440 The number of COVID-19 patients is increasing dramatically worldwide and
441 the early recognition of severe forms of COVID-19 is essential for timely triaging
442 of patients. Some model analysis showed that IL-6 and CRP could be used as
443 independent factors to predict the severity of COVID-19 (52). IL-6 is a

444 multifunctional cytokine that presented a strong proinflammatory effect with
445 functions in inflammation, tumor, and hematological diseases (53,54). Other work
446 suggested that the predictive values of IL-10 and IL-6 should be preferentially
447 evaluated for early diagnosis of patients with severe disease (18). IL-10 is highly
448 abundant, especially during the adaptive immune response (55). Although, some
449 studies pointed that plasma IL-6 and IL-10 levels could be used as a factor to
450 predict the progression of COVID-19, in our cohort these values alone did not
451 distinguish the severe and critical groups, but these cytokines were in lower levels
452 in mild/moderate disease and higher expression was observed in some patients
453 with severe/critical COVID-19. Patients with severe COVID-19 disease presented
454 with increased leukocytosis, neutrophilia, lymphopenia, and thrombocytopenia
455 than those with non-severe disease (56); and we also demonstrated a significant
456 correlation between plasma sTREM-1 and those hematological parameters in
457 severe COVID-19.

458 Instead, sTREM-1 levels were found to be independent discriminators of
459 disease severity on admission, we also comprised that sTREM-1 could be an
460 outcome predictor for patients with COVID-19. Therefore, markedly elevated
461 plasma sTREM-1 levels in patients with COVID-19 might be the indication of
462 excessive inflammatory response and contribute to severe/critical illness or even
463 death. Generally, the most common therapeutic options for viral infections are
464 directed at either blocking viral replication or modulation of immune response.
465 Dexamethasone exhibits broad-spectrum anti-inflammatory effects. In patients
466 hospitalized with COVID-19, the use of dexamethasone resulted in lower
467 mortality (57). We observed a longitudinal sTREM-1 detection in patient
468 admission and outcome in hospital care; in patients with non-treatment with
469 dexamethasone, sTREM-1 increased after admission and correlated with
470 outcome death. However, patients that were treated with dexamethasone, in
471 mostly the case, control and reduced the sTREM-1 production, but this
472 phenomenon was not correlated with better recovery. It means a non-return point
473 to anti-inflammatory treatment in COVID-19, and sTREM-1 value could expose
474 that inflammatory status. It is likely that the beneficial effect of glucocorticoids in
475 severe COVID-19 is subject on a selection of dose and time.

476 There are some limitations in our study. First, chronic diseases and
477 secondary infection in some cases might exert effects on the increased plasma
478 sTREM-1 level besides SARS-CoV-2 infection itself. Second, this study was
479 limited by sample size. Larger studies with continuous monitoring of sTREM-1
480 are necessary to further confirm the prognostic effect in patients with severe
481 COVID-19. Exacerbation of the situation is usually a dynamic process; thus the
482 data at a certain time point may not accurately reflect change in the patient
483 condition. Third, some patients with critical illness were not admitted to intensive
484 care unit, which definitely had a negative impact on the outcome of those patients.
485 Although our findings should be evaluated with larger number of samples by
486 multi-center research, sTREM-1 is a potential marker of diagnostic to distinguish
487 critical COVID-19 and poor-outcome, and monitoring the sTREM-1 levels will
488 improve treatment efficacy and reduce mortality.

489 **CONCLUSION**

490 In conclusion, our results suggested that admission plasma sTREM-1
491 levels play an important role in discriminating disease severity and predicting
492 adverse outcome in patients with COVID-19. Patients with markedly elevated
493 admission sTREM-1 should be provided more attention and supported treatment.
494 In this perspective, we suggested the sTREM-1 value contribution to the clinical
495 course of COVID-19 infection and highlight potential strategies for therapeutic
496 intervention. Also, emerged as a possible prognostic biomarker readily detected
497 in plasma of COVID-19 patients.

498 **ACKNOWLEDGEMENTS**

499 The authors acknowledge the support of the ICU team of doctors, nurses,
500 physiotherapists and the collaboration of *Hospital Santa Casa de Misericórdia of*
501 *Ribeirão Preto* and *Hospital São Paulo of Ribeirão Preto*. The laboratory support
502 from Supera Parque - Innovation and Technology Park- Ribeirão Preto/SP for
503 testing infection by SARS-CoV-2 in healthy volunteers. The valuable contribution
504 by Municipal Health Department of Ribeirão Preto city and Analysis Service
505 Clinics (SAC) from Faculdade de Ciências Farmacêuticas de Ribeirão Preto –
506 USP. We are grateful to Fabiana R. de Moraes for helping with Flow Cytometer

507 analysis; and Professors Victor Hugo Aquino Quintana and Márcia Regina von
508 Zeska Kress for sharing viral BSL2 lab.

509 **Supplementary Data**

510 **Supplemental Table 1. Hospital support, supportive therapies and**
511 **medications of patients severe and critical infected with SARS-CoV-2.**

512

During hospital stay	Severe/critical N=19
Hospital support, No. (%)	
Infirmery	9 (47.36)
Intensive care unit (ICU)	10 (52.63)
Hospitalization data, No.	
Hospitalization days, median (IQR)	10 (8-22)
Number of days since symptom onset (IQR)	6 (2-15)
Respiratory support received (%)	
Nasal-cannula oxygen	5 (26.31)
Non-rebreathing mask / Noninvasive ventilation	8 (42.10)
Invasive mechanical ventilation	6 (31.57)
Oxygen Saturation median (IQR)	93 (70-99)
Medications	
Dexamethasone	14 (73.68)
Azithromycin	14 (73.68)
Ceftriaxone	13 (68.42)
Oseltamivir	12 (63.15)
Cloroquine/Hydroxychloroquine	5 (26.31)
Anticoagulant	1 (5.26)
Death	17 (89.4)

513

Abbreviation: IQR, interquartile range, Data are median (IQR), n (%), or n/N.

514 **Supplemental Table 2. Information about r and p-values of the correlation**
515 **matrix of the graph shown in figure 2.**

Comparison	Row	Column	Correlation	p-value
1	sTREM1	Lymphocytes	-0,52170	1,14E-06
2	sTREM1	Neutrophils	0,58800	1,88E-08
3	Lymphocytes	Neutrophils	-0,44264	5,55E-05
4	sTREM1	Glycemia	0,09286	0,42182
5	Lymphocytes	Glycemia	-0,36861	0,00097
6	Neutrophils	Glycemia	0,09778	0,39753
7	sTREM1	IL10	0,42499	0,00012
8	Lymphocytes	IL10	-0,26048	0,02214
9	Neutrophils	IL10	0,27028	0,01744
10	Glycemia	IL10	0,12544	0,27703
11	sTREM1	IL6	0,43267	8,50E-05

12	Lymphocytes	IL6	-0,16860	0,14271
13	Neutrophils	IL6	0,35654	0,00146
14	Glycemia	IL6	-0,04650	0,68803
15	IL10	IL6	0,27826	0,01427
16	sTREM1	Mild	-0,42227	0,00011
17	Lymphocytes	Mild	0,64575	2,28E-10
18	Neutrophils	Mild	-0,34410	0,00218
19	Glycemia	Mild	-0,26277	0,02095
20	IL10	Mild	-0,17832	0,12075
21	IL6	Mild	-0,14227	0,21709
22	sTREM1	Moderate	-0,26402	0,01871
23	Lymphocytes	Moderate	0,25992	0,02244
24	Neutrophils	Moderate	-0,33536	0,00287
25	Glycemia	Moderate	-0,23557	0,03917
26	IL10	Moderate	-0,17433	0,12942
27	IL6	Moderate	-0,14347	0,21321
28	Mild	Moderate	-0,28445	0,01107
29	sTREM1	Severe	-0,04560	0,69176
30	Lymphocytes	Severe	-0,40727	0,00026
31	Neutrophils	Severe	0,17927	0,12125
32	Glycemia	Severe	0,52996	8,52E-07
33	IL10	Severe	-0,02137	0,85461
34	IL6	Severe	-0,03733	0,74885
35	Mild	Severe	-0,35237	0,00156
36	Moderate	Severe	-0,36560	0,00100
37	sTREM1	Critical	0,68800	6,59E-12
38	Lymphocytes	Critical	-0,44213	8,02E-05
39	Neutrophils	Critical	0,45144	5,41E-05
40	Glycemia	Critical	-0,05256	0,65648
41	IL10	Critical	0,45644	4,36E-05
42	IL6	Critical	0,37704	0,00093
43	Mild	Critical	-0,27454	0,01639
44	Moderate	Critical	-0,28493	0,01261
45	Severe	Critical	-0,33736	0,00288
46	sTREM1	Male	0,19819	0,08197
47	Lymphocytes	Male	-0,39743	0,00038
48	Neutrophils	Male	0,15473	0,18202
49	Glycemia	Male	0,28389	0,01295
50	IL10	Male	0,15893	0,17027
51	IL6	Male	-0,02913	0,80277
52	Mild	Male	-0,21052	0,06431
53	Moderate	Male	-0,17884	0,11721
54	Severe	Male	0,17882	0,11725

55	Critical	Male	0,20958	0,06921
56	sTREM1	Age	0,43058	8,32E-05
57	Lymphocytes	Age	-0,64649	2,83E-10
58	Neutrophils	Age	0,43821	7,52E-05
59	Glycemia	Age	0,33385	0,00321
60	IL10	Age	0,33105	0,00349
61	IL6	Age	0,27897	0,01467
62	Mild	Age	-0,50132	2,94E-06
63	Moderate	Age	-0,32776	0,00340
64	Severe	Age	0,41118	0,00020
65	Critical	Age	0,39176	0,00051
66	Male	Age	0,33291	0,00309
67	sTREM1	Systole	0,12566	0,27942
68	Lymphocytes	Systole	-0,10523	0,37222
69	Neutrophils	Systole	-0,03093	0,79362
70	Glycemia	Systole	0,12893	0,27360
71	IL10	Systole	-0,11298	0,33785
72	IL6	Systole	-0,05190	0,66054
73	Mild	Systole	-0,03689	0,75175
74	Moderate	Systole	-0,05579	0,63217
75	Severe	Systole	-0,04354	0,70879
76	Critical	Systole	0,11156	0,34401
77	Male	Systole	-0,02091	0,85768
78	Age	Systole	0,02243	0,84853
79	sTREM1	SaO ₂	0,02523	0,82987
80	Lymphocytes	SaO ₂	0,25259	0,02991
81	Neutrophils	SaO ₂	-0,07563	0,52189
82	Glycemia	SaO ₂	-0,03030	0,79774
83	IL10	SaO ₂	-0,02714	0,81847
84	IL6	SaO ₂	0,03383	0,77480
85	Mild	SaO ₂	0,17241	0,13911
86	Moderate	SaO ₂	0,12471	0,28640
87	Severe	SaO ₂	-0,07139	0,54555
88	Critical	SaO ₂	-0,24686	0,03658
89	Male	SaO ₂	-0,11772	0,31784
90	Age	SaO ₂	-0,31813	0,00574
91	Systole	SaO ₂	0,03868	0,74523

517 **NOTES**

518 *Author Contributions.*

519 PVSN, JCSC, CAS and conceptualization the study. PVSN, JCSC, VEP, NTN
520 performed the main experimental procedure. MMP, supervised the collection of
521 samples from patients. PVSN, JCSC, YCG, ACX, GSP, ICG, KZ, CT G, JGMA,
522 AAFJ, help with samples collection. PVSN, JCSC, TFCFS, CMM, LCR, CFSLD,
523 sample processed and fractionation. CNSO, YCG, TFCFS, CRBC, performed the
524 main experimental cytokines measurement. SRM, analyzed the data by R
525 program. PVSN, DMT, CAS, performed the statistical analysis of the data and
526 wrote the article and prepared the figures. DPS, DCN, RCS, LFC, RCCB, APA,
527 AMD, FMO, MRF, RSP, FCV, GGG, JJRR, OF, contributed to the collection of
528 clinical specimens, demographic, helped clinical data management and clinical
529 characteristics analysis from COVID-19 patients. PVSN, DMT, CAS, drafted the
530 manuscript. All authors helped editing the manuscript. CAS and LHF supervised
531 the project. FGF, VLDB, CRBC and LHF, provided study materials, reagents and
532 other analysis tools and equipment. CAS, FGF, SRCM, EMSR, ALV, APMF,
533 IKFMS, VLDB, CRBC, MDB, AM, RTS, LHF, coordination and idealization of the
534 project; and critical revision of the manuscript for important intellectual concept.
535 All authors have read and agreed to the published version of the manuscript.

536 *Financial support.*

537 This work was supported by Fundação de Amparo à Pesquisa do Estado de São
538 Paulo – FAPESP (grants n. 2014/07125-6, 2020/05207-6 for LHF and grant n.
539 2020/05270-0 for VDB); Fundação de apoio à Universidade de São Paulo –FUSP
540 by USP VIDA program. Coordenação de Aperfeiçoamento de Pessoal de Nível
541 Superior (CAPES - Finance Code 001); Fundação de Amparo à Pesquisa do
542 Estado do Amazonas - FAPEAM and from Conselho Nacional de
543 Desenvolvimento Científico e Tecnológico (CNPq). RTS is funded by NIH (R01
544 HL144478) and Department of Veterans Affairs (I01 BX001786).

545 *Conflict of interest statement*

546 The authors declare that the research was conducted in the absence of any
547 commercial or financial relationships that could be construed as a potential
548 conflict of interest.

549 REFERENCES

- 550 1. Zhou P, Yang X Lou, Wang XG, Hu B, Zhang L, Zhang W, et al. A
551 pneumonia outbreak associated with a new coronavirus of probable bat
552 origin. *Nature*. 2020;579(7798):270–273.
- 553 2. Velavan TP, Meyer CG. The COVID-19 epidemic. *Trop Med Int Heal*.
554 2020;25(3):278–80.
- 555 3. Zhang Y-Z. Novel 2019 coronavirus genome. Shanghai Public Health
556 Clinical Center & School of Public Health. 2020.
- 557 4. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The
558 proximal origin of SARS-CoV-2. *Nat Med*. 2020;26(April):450–2.
- 559 5. Ministério da Saúde. Protocolo de Manejo Clínico para o Novo
560 Coronavírus (2019-nCoV). 2020. p. 1 ed.
- 561 6. Dan Xu M, Fuling Zhou M, Wenbo Sun M, Liangjun Chen M, Lan Lan M,
562 Huan Li M, et al. Relationship Between serum SARS-CoV-2 nucleic
563 acid(RNAemia) and Organ Damage in COVID-19 Patients: A Cohort
564 Study. *Clin Infect Dis*. 2020;
- 565 7. Becker RC. COVID-19 update: Covid-19-associated coagulopathy. *J*
566 *Thromb Thrombolysis* [Internet]. 2020;50(1):54–67. Available from:
567 <https://doi.org/10.1007/s11239-020-02134-3>
- 568 8. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and
569 anticoagulation. *Blood*. 2020;135(23):2033–40.
- 570 9. Dupont V, Kanagaratnam L, Goury A, Poitevin G, Bard M, Julien G, et al.
571 Excess soluble fms-like tyrosine kinase 1 correlates with endothelial
572 dysfunction and organ failure in critically ill COVID-19 patients. *Clin Infect*
573 *Dis*. 2020;
- 574 10. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of
575 patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*.
576 2020;395(10223):497–506.
- 577 11. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and
578 immunological features of severe and moderate coronavirus disease
579 2019. *J Clin Invest*. 2020;130(5):2620–9.
- 580 12. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the
581 Coronavirus Disease 2019 (COVID-19) Outbreak in China. *JAMA*.
582 2020;323(13):1239–42.
- 583 13. Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F, et al.
584 Obesity in Patients Younger Than 60 Years Is a Risk Factor for COVID-
585 19 Hospital Admission. *Clin Infect Dis*. 2020;71(15):896–897.
- 586 14. Henry B, de Oliveira M, Benoit S, Plebani M L. Hematologic, biochemical
587 and immune biomarker abnormalities associated with severe illness and
588 mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. *Clin*
589 *Chem Lab Med*. 2020;58(7):1021–8.

- 590 15. Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19:
591 immunity, inflammation and intervention. *Nat Rev Immunol* [Internet].
592 2020;20(6):363–74. Available from: [http://dx.doi.org/10.1038/s41577-020-](http://dx.doi.org/10.1038/s41577-020-0311-8)
593 0311-8
- 594 16. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of
595 immune response in patients with COVID-19 in Wuhan, China. *Clin Infect*
596 *Dis*. 2020;71(15):762–768.
- 597 17. Chen L, Liu HG, Liu W, Liu J, Liu K, Shang J, et al. [Analysis of clinical
598 features of 29 patients with 2019 novel coronavirus pneumonia].
599 *Zhonghua Jie He He Hu Xi Za Zhi*. 2020;
- 600 18. Han H, Ma Q, Li C, Liu R, Zhao L, Wang W, et al. Profiling serum
601 cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease
602 severity predictors. *Emerg Microbes Infect*. 2020;9(1):1123–30.
- 603 19. Wang G, Wu C, Zhang Q, Wu F, Yu B, Lv J, et al. C-reactive protein level
604 may predict the risk of COVID-19 aggravation. *Open Forum Infect Dis*.
605 2020;7(5):1–5.
- 606 20. Xiaomin Luo M, Wei Zhou M, Xiaojie Yan M, Tangxi Guo M, Benchao
607 Wang, MD Hongxia Xia M, Lu Ye M, et al. Prognostic value of C-reactive
608 protein in patients with COVID-19. *Clin Infect Dis* [Internet].
609 2020;23(ciaa641). Available from: [10.1093/cid/ciaa641](https://doi.org/10.1093/cid/ciaa641)
- 610 21. Yao Y, Cao J, Wang Q, Shi Q, Liu K, Luo Z, et al. D-dimer as a biomarker
611 for disease severity and mortality in COVID-19 patients: A case control
612 study. *J Intensive Care*. 2020;8(49).
- 613 22. Takeuchi O, Akira S. Innate immunity to virus infection. *Immunol Rev*.
614 2009;227(1):75–86.
- 615 23. Adukpo S, Gyan BA, Ofori MF, Dodoo D, Velavan TP, Meyer CG.
616 Triggering receptor expressed on myeloid cells 1 (TREM-1) and cytokine
617 gene variants in complicated and uncomplicated malaria. *Trop Med Int*
618 *Heal*. 2016;21(12):1592–601.
- 619 24. Ford JW, McVicar DW. TREM and TREM-like receptors in inflammation
620 and disease. *Current Opinion in Immunology*. 2009.
- 621 25. Chen LC, Laskin JD, Gordon MK, Laskin DL. Regulation of TREM
622 expression in hepatic macrophages and endothelial cells during acute
623 endotoxemia. *Exp Mol Pathol*. 2008;
- 624 26. Hommes TJ, Dessing MC, van 't Veer C, Florquin S, Colonna M, de Vos
625 AF, et al. TREM-1/3 Contribute to Protective Immunity in Klebsiella
626 Derived Pneumosepsis Whereas TREM-2 Does Not. *Am J Respir Cell*
627 *Mol Biol*. 2015;
- 628 27. de Oliveira Matos A, Dantas P, Silva-Sales M, Sales-Campos H. The role
629 of the triggering receptor expressed on myeloid cells-1 (TREM-1) in non-
630 bacterial infections. *Crit Rev Microbiol* [Internet]. 2020;46(3):237–52.
631 Available from: <https://doi.org/10.1080/1040841X.2020.1751060>

- 632 28. Dantas PH dos S, Matos A de O, da Silva Filho E, Silva-Sales M, Sales-
633 Campos H. Triggering receptor expressed on myeloid cells-1 (TREM-1)
634 as a therapeutic target in infectious and noninfectious disease: a critical
635 review. *Int Rev Immunol* [Internet]. 2020;0(0):1–15. Available from:
636 <https://doi.org/10.1080/08830185.2020.1762597>
- 637 29. Arts R, Joosten L, van der Meer J, Netea M. TREM-1: intracellular
638 signaling pathways and interaction with pattern recognition receptors. *J*
639 *Leukoc Biol*. 2013;93(2):209–15.
- 640 30. Weber B, Schuster S, Zysset D, Rihs S, Dickgreber N, Schürch C, et al.
641 TREM-1 Deficiency Can Attenuate Disease Severity without Affecting
642 Pathogen Clearance. *PLoS Pathog*. 2014;10(1):e1003900.
- 643 31. Yuan Z, Petree JR, Lee FEH, Fan X, Salaita K, Guidot DM, et al.
644 Macrophages exposed to HIV viral protein disrupt lung epithelial cell
645 integrity and mitochondrial bioenergetics via exosomal microRNA
646 shuttling. *Cell Death Dis*. 2019;10(8):580.
- 647 32. Tamaro A, Derive M, Gibot S, Leemans JC, Florquin S, Dessing MC.
648 TREM-1 and its potential ligands in non-infectious diseases: from biology
649 to clinical perspectives. *Pharmacol Ther* [Internet]. 2017;177:81–95.
650 Available from: <http://dx.doi.org/10.1016/j.pharmthera.2017.02.043>
- 651 33. Cao C, Gu J, Zhang J. Soluble triggering receptor expressed on myeloid
652 cell-1 (sTREM-1): a potential biomarker for the diagnosis of infectious
653 diseases. *Front Med*. 2017;11(2):169–77.
- 654 34. Kuemmel A, Alflen A, Schmidt LH, Sebastian M, Wiewrodt R, Schulze AB,
655 et al. Soluble Triggering Receptor Expressed on Myeloid Cells 1 in lung
656 cancer. *Sci Rep*. 2018;8(10766):1–9.
- 657 35. Klesney-Tait J, Turnbull IR, Colonna M. The TREM receptor family and
658 signal integration. *Nat Immunol*. 2006;7:1266–1273.
- 659 36. Gómez-piña V, Soares-schanoski A, Rodríguez-rojas A, Fresno C, García
660 F, Vallejo-cremades MT, et al. Metalloproteinases Shed TREM-1
661 Ectodomain from Lipopolysaccharide-stimulated Human Monocytes. *J*
662 *Immunol* [Internet]. 2007;179:4065–73. Available from:
663 <http://www.jimmunol.org/content/179/6/4065.long>
- 664 37. Li Z, Zhang E, Hu Y, Liu Y, Chen B. High Serum sTREM-1 Correlates
665 With Myocardial Dysfunction and Predicts Prognosis in Septic Patients.
666 *Am J Med Sci*. 2016;351(6):555–62.
- 667 38. Jedynak M, Siemiatkowski A, Mroczko B, Groblewska M, Milewski R,
668 Szmitkowski M. Soluble TREM-1 Serum Level can Early Predict Mortality
669 of Patients with Sepsis, Severe Sepsis and Septic Shock. *Arch Immunol*
670 *Ther Exp (Warsz)*. 2018;66:299–306.
- 671 39. Huang CT, Lee LN, Ho CC, Shu CC, Ruan SY, Tsai YJ, et al. High serum
672 levels of procalcitonin and soluble TREM-1 correlated with poor prognosis
673 in pulmonary tuberculosis. *J Infect*. 2014;68(5):440–7.
- 674 40. Guideline C. Diagnosis and treatment protocol for novel coronavirus

- 675 pneumonia (Trial version 7). *Chin Med J (Engl)*. 2020;133(9):1087–95.
- 676 41. Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, et al. Clinical features and
677 treatment of COVID-19 patients in northeast Chongqing. *J Med Virol*.
678 2020;0–1.
- 679 42. Wei T, Simko V, Levy M, Xie Y, Jin Y, Zemla J. Package ‘corrplot.’
680 *Statisticians*. 2017;56(316):e24.
- 681 43. Harrell FE. With contributions from Charles Dupont and many others
682 (2017). “Hmisc: Harrell Miscellaneous”. R package version 4.0-1. 2020. p.
683 1–433.
- 684 44. Yang P, Ding Y, Xu Z, Pu R, Li P, Yan J, et al. Epidemiological and
685 clinical features of COVID-19 patients with and without pneumonia in
686 Beijing, China. *Medrxiv*. 2020;
- 687 45. Zumla A, Hui DS, Azhar EI, Memish ZA, Maeurer M. Reducing mortality
688 from 2019-nCoV: host-directed therapies should be an option. *Lancet*.
689 2020;395(10224):e35–e36.
- 690 46. Zheng H, Heiderscheidt CA, Joo M, Gao X, Knezevic N, Mehta D, et al.
691 MYD88-dependent and -independent activation of TREM-1 via specific
692 TLR ligands. *Eur J Immunol*. 2010;40(1):162–71.
- 693 47. Dimopoulou I, Pelekanou A, Mavrou I, Savva A, Tzanela M, Kotsaki A, et
694 al. Early serum levels of soluble triggering receptor expressed on myeloid
695 cells-1 in septic patients: Correlation with monocyte gene expression. *J*
696 *Crit Care*. 2012;27(3):294–300.
- 697 48. Gibot S, Cravoisy A, Levy B, Bene MC, Faure G, Bollaert PE. Soluble
698 Triggering Receptor Expressed on Myeloid Cells and the Diagnosis of
699 Pneumonia. *N Engl J Med*. 2004;350:451–8.
- 700 49. Yuan Z, Syed M, Panchal D, Joo M, Bedi C, Lim S, et al. TREM-1-
701 accentuated lung injury via miR-155 is inhibited by LP17 nanomedicine.
702 *Am J Physiol - Lung Cell Mol Physiol*. 2016;310(5):L426-38.
- 703 50. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: A
704 novel understanding of the disorder and a new therapeutic approach.
705 *Lancet Infect Dis*. 2013;13(3):260–8.
- 706 51. Richard-Greenblatt M, Boillat-Blanco N, Zhong K, Mbarack Z, Samaka J,
707 Mlaganile T, et al. Prognostic Accuracy of Soluble Triggering Receptor
708 Expressed on Myeloid Cells (sTREM-1)-based Algorithms in Febrile
709 Adults Presenting to Tanzanian Outpatient Clinics. *Clin Infect Dis*.
710 2020;70(7):1304–1312.
- 711 52. Liu F, Li L, Xu M Da, Wu J, Luo D, Zhu YS, et al. Prognostic value of
712 interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-
713 19. *J Clin Virol*. 2020;127:104370.
- 714 53. Taniguchi K, Karin M. IL-6 and related cytokines as the critical lynchpins
715 between inflammation and cancer. *Semin Immunol*. 2014;26:54–74.
- 716 54. Lai HS, Lin WH, Lai SL, Lin HY, Hsu WM, Chou CH, et al. Interleukin-6

- 717 Mediates Angiotensinogen Gene Expression during Liver Regeneration.
718 PLoS One. 2013;e67868.
- 719 55. McKinstry KK, Strutt TM, Buck A, Curtis JD, Dibble JP, Huston G, et al.
720 IL-10 Deficiency Unleashes an Influenza-Specific Th17 Response and
721 Enhances Survival against High-Dose Challenge. J Immunol.
722 2009;182(12):7353–7363.
- 723 56. Vardhana SA, Wolchok JD. The many faces of the anti-COVID immune
724 response. J Exp Med. 2020;217(6):e20200678.
- 725 57. The RECOVERY Collaborative G. Dexamethasone in Hospitalized
726 Patients with Covid-19 — Preliminary Report. N Engl J Med. 2020;
727